

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華熙生物科技有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00963)

**RESULTS OF THE 2009 ANNUAL GENERAL MEETING
RE-ELECTION OF RETIRING DIRECTORS**

The Board is pleased to announce that all the resolutions as set out in the AGM Notice were duly passed at the AGM held on 20 May 2010.

Reference is made to the notice of 2009 annual general meeting (the “AGM”) dated 21 April 2010 (the “AGM Notice”) of Bloomage BioTechnology Corporation Limited (the “Company”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated 21 April 2010.

RESULTS OF AGM

The board of directors (the “Board”) of the Company announces that, at the AGM held at Unit 3203, 32nd Floor, Admiralty Centre I, 18 Harcourt Road, Hong Kong on 20 May 2010 at 10:00 a.m., poll voting was adopted for all of the resolutions as set out in the AGM Notice (the “Resolutions”).

The Board is pleased to announce that the Resolutions were duly passed by the shareholders of the Company (the “Shareholders”) by poll voting at the AGM. The poll results for the Resolutions are as follows.

Ordinary Resolutions	Number of Votes (%)		Total Votes
	For	Against	
1. To receive and consider the audited consolidated accounts and reports of the directors and auditors of the Company and its subsidiaries for the year ended 31 December 2009	194,220,000 (100%)	0 (0%)	194,220,000
2. To declare a final dividend for the year ended 31 December 2009	194,220,000 (100%)	0 (0%)	194,220,000
3. To re-appoint KPMG as auditors of the Company and to authorise the board of directors of the Company to fix their remuneration	194,220,000 (100%)	0 (0%)	194,220,000
4. (a) Mr. Guo Jiajun be re-elected as an executive director of the Company and the board of directors of the Company be authorised to fix his director’s remuneration	194,220,000 (100%)	0 (0%)	194,220,000
(b) Mr. Cheng Bo be re-elected as a non-executive director of the Company and the board of directors of the Company be authorised to fix his director’s remuneration	194,220,000 (100%)	0 (0%)	194,220,000
5. To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company as at the date of passing this resolution	194,220,000 (100%)	0 (0%)	194,220,000

Ordinary Resolutions	Number of Votes (%)		Total Votes
	For	Against	
6. To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company as at the date of passing this resolution	194,220,000 (100%)	0 (0%)	194,220,000
7. To extend the general mandate granted to the directors of the Company to allot, issue and deal with additional shares in the share capital of the Company by an amount not exceeding the amount of the shares repurchased by the Company	194,220,000 (100%)	0 (0%)	194,220,000

The description of the Resolutions above is by way of summary only. The full text appears in the AGM Notice.

As more than 50% of the votes were cast in favour of the Resolutions, the Resolutions were duly passed as ordinary resolutions of the Company.

The Hong Kong branch share registrar and transfer office of the Company, Tricor Investor Services Limited was appointed as the scrutineer for the poll voting at the AGM.

Notes:

- (a) The total number of shares of the Company in issue as at the date of the AGM: 312,000,000 shares of HK\$0.01 each. No Shareholder was required to abstain from voting on the Resolutions at the AGM.
- (b) The total number of shares of the Company entitling the holders to attend and vote only against the Resolutions at the AGM: Nil.
- (c) The total number of shares of the Company entitling the holders to attend and to vote for or against the Resolutions at the AGM: 312,000,000 shares.

RE-ELECTION OF MR. GUO JIAJIN (SONG) AS AN EXECUTIVE DIRECTOR

At the AGM, the re-election of Mr. Guo Jiajun (Song) as an executive Director was duly approved by the Shareholders and such appointment took effect immediately thereafter.

Mr. Guo Jiajun (Song) (郭珈均(嵩)), aged 34, is an executive Director and the chief executive officer of the Company. He graduated from Shandong University at Weihai (山東大學威海分校) in 1998 with a bachelor degree of science with major in electronics and information systems and completed an international MBA program organised by the China Center for Economic Research at Peking University from 2005 to 2008, and was awarded a master degree of business administration by Fordham University of the US in 2008. He worked for the Housing Fund Management Centre of Weihai Finance Bureau in Shandong (山東省威海市住房公積金管理中心) as a staff member and was responsible for the management and payment of housing funds from 1998 to 2001. He was the manager of the administration department of Bloomage Investment Co., Ltd. (華熙中環投資有限公司), an investment holding company (the subsidiaries of which are principally engaged in property development and investments in the PRC as well as operation and management of stadium and commercial projects in the PRC). He is primarily responsible for the Group's strategic development and investment planning. He is also responsible for supervising the management team of the Group to implement and execute decisions of the Board. He is a director of Shandong Freda Biopharmaceutical Co., Ltd. ("Freda Biopharm"). He joined the Group in March 2006.

Save as disclosed above, Mr. Guo did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group and did not have other major appointments and professional qualifications.

Save as disclosed above, Mr. Guo does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company and he had no interests in the Shares which are required to be disclosed pursuant to Part XV of the SFO.

Mr. Guo has entered into a director's service contract with the Company for an initial term of two years commencing from 3 October 2009, which may be terminated by either party thereto by giving the other party not less than three months' prior notice in writing and is entitled to receive an annual salary of HK\$200,000 which is determined with reference to the prevailing market practice, the Company's remuneration policy, his duties and responsibilities with the Group.

Save as disclosed above, there are no other matters relating to the re-election that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to paragraph 13.51(2)(h) to (v) of the Listing Rules.

RE-ELECTION OF MR. CHENG BO AS A NON-EXECUTIVE DIRECTOR

At the AGM, the re-election of Mr. Cheng Bo as a non-executive Director was duly approved by the Shareholders and such appointment took effect immediately thereafter.

Mr. Cheng Bo (程波), aged 49, is a non-executive Director. Mr. Cheng completed a postgraduate course in management science and engineering organised by the University of Electronic Science and Technology of China (電子科技大學) from 1999 to 2001. Mr. Cheng also completed an advanced study program in business administration at Renmin University of China (中國人民大學) from 2001 to 2003.

Mr. Cheng had been working at Shandong Bausch & Lomb Freda Pharmaceutical Co., Ltd. (山東博士倫福瑞達製藥有限公司), a company principally engaged in the research, production and sale of biochemical drugs including eye drugs from 1991 to December 2009. Mr. Cheng was the vice-president of Shandong Bausch & Lomb Freda Pharmaceutical Co. Ltd.. He has been a director of Freda Biopharm since October 1999. Mr. Cheng is a director of Newgrand Holdings Limited which holds 9% interest in the Company.

Save as disclosed above, Mr. Cheng did not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years or any other position with the Company and other members of the Group and did not have other major appointments and professional qualifications.

As at the Latest Practicable Date, 28,080,000 Shares (approximately 9% of the issued share capital of the Company) were held by Newgrand Holdings Limited (“Newgrand”), which was in turn wholly-owned by Mr. Cheng. Therefore, Mr. Cheng is deemed, or taken to be, interested in all the Shares which are beneficially owned by Newgrand for the purposes of the SFO.

Save as disclosed above, Mr. Cheng does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company and he had no interests in the Shares which are required to be disclosed pursuant to Part XV of the SFO.

Mr. Cheng has entered into a director’s service contract with the Company for an initial term of two years commencing from 3 October 2009, which may be terminated by either party thereto by giving the other party not less than one month’s prior notice in writing and is entitled to receive an annual salary of HK\$100,000 which is determined with reference to the prevailing market practice, the Company’s remuneration policy, his duties and responsibilities with the Group.

Save as disclosed above, there are no other matters relating to the re-election that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to paragraph 13.51(2)(h) to (v) of the Listing Rules.

By Order of the Board
Bloomage BioTechnology Corporation Limited
Zhao Yan
Chairman

Hong Kong, 20 May 2010

As at the date of this announcement, the executive Directors are Ms. Zhao Yan and Mr. Guo Jiajun; the non-executive Director is Mr. Cheng Bo; and the independent non-executive Directors are Ms. Zhan Lili, Mr. Zhang Fuping and Mr. Qin Bin.